Tommaso Perini

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Cytarabine as a salvage mobilization strategy after failure of cyclophosphamide-based stem cell collection for Daratumumab-treated multiple myeloma patients.

Cytarabine as a salvage mobilization strategy after failure of cyclophosphamide-based stem cell collection for Daratumumab-treated multiple myeloma patients.

Journal: Leukemia & lymphoma
Published: May 08, 2026

The C-terminal region of TENT5 proteins drives ER-associated mRNA polyadenylation via FNDC3 interaction.

The C-terminal region of TENT5 proteins drives ER-associated mRNA polyadenylation via FNDC3 interaction.

Journal: Cell reports
Published: October 14, 2025

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Journal: Blood cancer discovery
Published: February 03, 2025

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma.

The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma.

Journal: Blood
Published: July 31, 2024

Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.

Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 17, 2024

A novel proteomic signature of osteoclast differentiation unveils the deubiquitinase UCHL1 as a necessary osteoclastogenic driver.

A novel proteomic signature of osteoclast differentiation unveils the deubiquitinase UCHL1 as a necessary osteoclastogenic driver.

Journal: Scientific reports
Published: January 16, 2024

TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma.

TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma.

Journal: Haematologica
Published: September 18, 2023

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma.

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma.

Journal: Haematologica
Published: May 02, 2023

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.

Journal: Frontiers in oncology
Published: April 30, 2022

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature.

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature.

Journal: Frontiers in oncology
Published: January 31, 2022

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial.

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial.

Journal: Frontiers in oncology
Published: June 27, 2021

The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.

The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.

Journal: The FEBS journal
Published: March 03, 2021
Showing 1-12 of 20

Last Updated: 09/26/2026